TransMedics Group (TMDX) Competitors

TransMedics Group (NASDAQ:TMDX) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.

Which has more risk & volatility, TMDX or SNN?

TransMedics Group has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Do insiders & institutionals believe in TMDX or SNN?

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer TMDX or SNN?

Smith & Nephew received 336 more outperform votes than TransMedics Group when rated by MarketBeat users. However, 58.85% of users gave TransMedics Group an outperform vote while only 54.16% of users gave Smith & Nephew an outperform vote.

Company	Underperform	Outperform
TransMedics Group	Outperform Votes 113 58.85%	Underperform Votes 79 41.15%
Smith & Nephew	Outperform Votes 449 54.16%	Underperform Votes 380 45.84%

Does the media refer more to TMDX or SNN?

In the previous week, TransMedics Group had 9 more articles in the media than Smith & Nephew. MarketBeat recorded 18 mentions for TransMedics Group and 9 mentions for Smith & Nephew. TransMedics Group's average media sentiment score of 0.89 beat Smith & Nephew's score of 0.86 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer TMDX or SNN?

TransMedics Group presently has a consensus target price of $124.20, indicating a potential upside of 34.99%. Smith & Nephew has a consensus target price of $27.00, indicating a potential downside of 3.57%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is TMDX or SNN more profitable?

TransMedics Group has a net margin of 8.14% compared to Smith & Nephew's net margin of 0.00%. TransMedics Group's return on equity of 18.74% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	8.14%	18.74%	4.39%
Smith & Nephew	N/A	N/A	N/A

Which has stronger valuation & earnings, TMDX or SNN?

Smith & Nephew has higher revenue and earnings than TransMedics Group. Smith & Nephew is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$441.54M	7.05	-$25.03M	$1.01	91.10
Smith & Nephew	$5.81B	2.11	$263M	$2.16	12.96

Summary

TransMedics Group beats Smith & Nephew on 15 of the 19 factors compared between the two stocks.